Recombinant Human Complement Factor H-related 5/CFHR5 is produced by our mammalian expression system in human cells. The target protein is expressed with sequence (Glu19-Glu569) of Human CFHR5 fused with a polyhistidine tag at the C-terminus.
Reinheit
> 95 % as determined by reducing SDS-PAGE.
Sterilität
0.2 μm filtered
Endotoxin-Niveau
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
Crystallography grade
CFHR5
Spezies: Human
Wirt: Insektenzellen
Recombinant
>95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot.
WB, SDS, ELISA, Crys
CFHR5
Spezies: Human
Wirt: HEK-293 Cells
Recombinant
> 80 % as determined by SDS-PAGE and Coomassie blue staining
AbP, STD
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Buffer
Lyophilized from a 0.2 μm filtered solution of 20 mM PB,150 mM NaCl, pH 7.4.
Handhabung
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Lagerung
4 °C/-20 °C/-80 °C
Informationen zur Lagerung
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
CFHL5 Protein, CFHR5D Protein, FHR-5 Protein, FHR5 Protein, complement factor H related 5 Protein, CFHR5 Protein
Sub Type
Fusionprotein
Hintergrund
Complement factor H-related protein 5(FHR-5 for short), is a secreted protein which contains 9 Sushi (CCP/SCR) domains. It is expressed by the liver and secreted in plasma. The pattern of the deposits is similar to other complement components, suggesting that FHR-5 may play a role in complement activation and regulation. Defects in CFHR5 have been found in patients with atypical hemolytic uremic syndrome and may contribute to the disease. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Alternative Names: